MetLife Investment Management’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $212K | Hold |
16,295
| – | – | ﹤0.01% | 2157 |
|
|
2025
Q1 | $173K | Sell |
16,295
-381
| -2% | -$4.04K | ﹤0.01% | 2276 |
|
|
2024
Q4 | $283K | Buy |
16,676
+2,955
| +22% | +$50.1K | ﹤0.01% | 2114 |
|
|
2024
Q3 | $318K | Hold |
13,721
| – | – | ﹤0.01% | 2031 |
|
|
2024
Q2 | $334K | Buy |
13,721
+1,394
| +11% | +$33.9K | ﹤0.01% | 1943 |
|
|
2024
Q1 | $416K | Hold |
12,327
| – | – | ﹤0.01% | 1781 |
|
|
2023
Q4 | $389K | Hold |
12,327
| – | – | ﹤0.01% | 1835 |
|
|
2023
Q3 | $315K | Hold |
12,327
| – | – | ﹤0.01% | 1914 |
|
|
2023
Q2 | $354K | Hold |
12,327
| – | – | ﹤0.01% | 1921 |
|
|
2023
Q1 | $295K | Hold |
12,327
| – | – | ﹤0.01% | 1969 |
|
|
2022
Q4 | $209K | Hold |
12,327
| – | – | ﹤0.01% | 2222 |
|
|
2022
Q3 | $183K | Hold |
12,327
| – | – | ﹤0.01% | 2355 |
|
|
2022
Q2 | $194K | Hold |
12,327
| – | – | ﹤0.01% | 2342 |
|
|
2022
Q1 | $332K | Buy |
12,327
+4,915
| +66% | +$133K | ﹤0.01% | 2036 |
|
|
2021
Q4 | $274K | Hold |
7,412
| – | – | ﹤0.01% | 1856 |
|
|
2021
Q3 | $354K | Sell |
7,412
-1,527
| -17% | -$73K | ﹤0.01% | 1730 |
|
|
2021
Q2 | $302K | Hold |
8,939
| – | – | ﹤0.01% | 1883 |
|
|
2021
Q1 | $369K | Hold |
8,939
| – | – | ﹤0.01% | 1695 |
|
|
2020
Q4 | $388K | Buy |
8,939
+1,855
| +26% | +$80.5K | ﹤0.01% | 1603 |
|
|
2020
Q3 | $304K | Buy |
7,084
+1,040
| +17% | +$44.6K | ﹤0.01% | 1624 |
|
|
2020
Q2 | $282K | Buy |
+6,044
| New | +$282K | ﹤0.01% | 1688 |
|